Sign in
Not yet recruitingPhase 2

Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Key facts

Who runs it
Sun Yat-sen University
Where
China3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
29 people, planned
Starts
1 Dec 2026
Expected to end
1 Dec 2029
Type of study
Interventional
Treatments tested
  • Tafasitamab
  • Lenalidomide
  • Rituximab
  • Orelabrutinib
Record updated
16 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • Willing to participate in the clinical study and signed informed consent
  • Age ≥18 years, no gender restrictions
  • Histologically confirmed relapsed or refractory diffuse large B-cell lymphoma; ineligible for or unable to access autologous stem cell transplantation (ASCT), chimeric antigen receptor T-cell (CAR-T) therapy
  • Has at least one measurable or assessable lesion
  • Eastern Cooperative Oncology Group performance status (ECOG PS) score ≤
  • Adequate major organ function

Who cannot take part

  • Disease progression following prior frontline treatment with a Bruton tyrosine kinase inhibitor (BTKi)
  • Active human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection
  • Inability to swallow capsules or significant gastrointestinal impairment that may affect drug absorption
  • Other progressive malignancy requiring active treatment
  • DLBCL with central nervous system involvement or Burkitt lymphoma

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Diffuse large B cell lymphoma

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a Phase II, Single-Arm, Open-Label, Prospective, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (TAFA) combined with Lenalidomide, Rituximab, and Orelabrutinib in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL).

The group in the trial

  • Tafasitamab in combination with Lenalidomide, Rituximab and OrelabrutinibTreatment being tested

    Participants will receive tafasitamab in combination with lenalidomide, rituximab and orelabrutinib for 4 cycles, and then receive tafasitamab and lenalidomide for additional 8 cycles. Each treatment cycle is 28 days.

    Treatment: Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Multicenter, Phase II Clinical Study of Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Criteria questions
Built from NCT07938619, who can take part
Record updated
16 November 2026